More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$64661756
EPS
-1.4
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.980955
Previous close
$1.48
Today's open
$1.49
Day's range
$1.40 - $1.50
52 week range
$1.31 - $19.40
show more
CEO
Christopher T. Giordano
Employees
14
Headquarters
Chapel Hill, NC
Exchange
NASDAQ Capital Market
Shares outstanding
45536448
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
Lead Plaintiff Deadline: December 28, 2026. Investors who purchased (NASDAQ: TENX) securities between November 13, 2023 and August 7, 2026 may be eligible to recover losses.
GlobeNewsWire • 8 hours ago

TENX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Tenax Therapeutics Securities Lawsuit - Contact Levi & Korsinsky
Important Information Regarding Section 20(a) Individual Liability Claims: Tenax's chief executive and three successive chief financial officers face control person claims over allegedly misleading statements about TNX-103. NEW YORK, Nov. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Tenax Therapeutics, Inc. (NASDAQ: TENX) that a pending securities class action names the Company's CEO and three successive CFOs as defendants.
PRNewsWire • 9 hours ago

Kaplan Fox Reminds Investors of a Securities Class Action Against Tenax Therapeutics, Inc. (TENX) - Deadline is December 28, 2026
New York, New York--(Newsfile Corp. - November 18, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Tenax and have suffered losses, you may CLICK HERE to contact us.
Newsfile Corp • 12 hours ago

TENX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tenax To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and reminds investors of the December 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Newsfile Corp • 9 hours ago

TENX Shareholder Alert: December 28, 2026 Lead Plaintiff Deadline in Tenax Therapeutics, Inc. Securities Class Action - Contact SueWallSt
Executive Accountability: Chief Medical Officer Stuart Rich is named in the Tenax securities action over his alleged assurances that the Phase 3 LEVEL study of TNX-103 was enriched with the patients most likely to respond. Executive Accountability: Chief Medical Officer Stuart Rich is named in the Tenax securities action over his alleged assurances that the Phase 3 LEVEL study of TNX-103 was enriched with the patients most likely to respond.
GlobeNewsWire • Nov 17, 2026

TENX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Tenax Therapeutics, Inc. and Encourages Investors to Contact the Firm
If you purchased or acquired Tenax securities between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
GlobeNewsWire • Nov 17, 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers – TENX
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) and certain officers. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 26-cv-01624, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
GlobeNewsWire • Nov 17, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
New York, New York--(Newsfile Corp. - November 17, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Tenax Therapeutics, Inc. (NASDAQ: TENX) between November 13, 2023 and August 7, 2026, both dates inclusive (the "Class Period"), of the important December 28, 2026 lead plaintiff deadline. SO WHAT: If you purchased Tenax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Newsfile Corp • Nov 17, 2026

TENX Investor Alert: Tenax Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Important Notice Regarding Alleged TNX-103 Efficacy Misrepresentations: the lawsuit claims Tenax promoted its Phase 3 LEVEL study as "derisked" while its lead drug candidate was allegedly less effective than represented.
GlobeNewsWire • Nov 16, 2026

Deadline Alert: Tenax Therapeutics, Inc. Investors Have Until December 28, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors
Class action covers investors who bought Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026; complaint alleges the company failed to disclose material adverse facts Class action covers investors who bought Tenax Therapeutics, Inc. securities between November 13, 2023 and August 7, 2026; complaint alleges the company failed to disclose material adverse facts
GlobeNewsWire • Nov 16, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tenax Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.